NSAIDs as cancer preventive agents

Asian Pacific Journal of Cancer Prevention

Volumn 1, Issue 2, 2000, Pages 97-113

  Wakabayashi, Keiji ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

Animal experimentation; Epidemiology; Inflammation; Mechanisms; Prevention

Indexed keywords

EID: 84873427559     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: None     Document Type: Review

References (257)

1. Abou-el-Ela SH, Prasse KW, Farrell RL, et al. (1989). Effects of D,L-2-difluoromethylornithine and indomethacin on mammary tumor promotion in rats fed high n-3 and/or n-6 fat diets [published erratum appears in Cancer Res 1989 Sep 1;49(17):4946]. Cancer Res, 49, 1434-40.
2. Achiwa H, Yatabe Y, Hida T, et al. (1999). Prognostic significance of elevated cyclooxygenase 2 expression in primary, resected lung adenocarcinomas. Clin Cancer Res, 5, 1001-5.
3. Akasu T, Yokoyama T, Sugihara K, et al. (2000). Peroral sustainedrelease indomethacin treatment for rectal adenomas in familial adenomatous polyposis: a pilot study. Hepato-gastroenterology (in press)
4. Alberts DS, Hixson L, Ahnen D, et al. (1995) Do NSAIDs exert their colon cancer chemoprevention activities through the inhibition of mucosal prostaglandin synthetase. J Cell Biochem, 22, 18-23.
5. Alexandrov VA, Bespalov VG, Petrov AS, Troyan DN, Lichks MY (1996). Study of post-natal effect of chemopreventive agents on ethylnitrosourea-induced transplacental carcinogenesis in rats. III. Inhibitory action of indomethacin, voltaren, theophylline and e-amniocaproic acid. Carcinogenesis, 17, 1935-39.
6. Ames BN, Gold LS, Willett WC (1995). The causes and prevention of cancer. Proc Natl Acad Sci USA, 92, 5258-65.
7. Barnes CJ, Cameron IL, Hardman WE, Lee M (1998). Non-steroidol anti-inflammatory drug effect on crypt cell proliferation and apoptosis during initiation of rat colon carcinogenesis. Br J Cancer, 77, 573-80.
8. Barnes CJ, Hamby-Mason RL, Hardman WE, et al. (1999). Effect of aspirin on prostaglandin E2 formation and transforming growth factor alpha expression in human rectal mucosa from individuals with a history of adenomatous polyps of the colon. Cancer Epidemiol Biomarkers Prevent 8, 311-5.
9. Bartram HP, Gostner A, Scheppach W, et al. (1993). Effects of fish oil on rectal cell proliferation, mucosal fatty acids, and prostaglandin E2 release in healthy subjects. Gastroenterology, 105, 1317-22.
10. Bauknecht T, Siegel A, Meerpohl HG, Zahradnik HP (1985). Formation of prostaglandins by ovarian carcinomas. Prostaglandins, 29, 665-72.
11. Bazan NG, Fletcher BS, Herschman HR, Mukherjee PK (1994). Platelet-activating factor and retinoic acid synergistically activate the inducible prostaglandin synthase gene. Proc Natl Acad Sci USA, 91, 5252-6.
12. Bennett A (1986). The production of prostanoids in human cancers, and their implications for tumor progression. Prog Lip Res, 25, 539-42.
13. Bespalov VG, Lidak MY, Petrov AS, Troyan DN, Alexandrov VA (1992). Study of anticarcinogenic effect of ortophen and indomethacin in rats and mice with induced tumours of different organs. Exp Oncol, 14, 36-40.
14. Bespalov VG, Troyan DN, Petrov AS, Alexandrov VA (1989). Inhibition of the esophagus tumor development by antiinflammatory non-steroidal and steroidal drugs indomethacin and dexamethasone. Pharmacol Toxicol, 52, 67-70.
15. Bjarnason I, Macpherson A, Rotman H, Schupp J, Hayllar J (1997). A randomized, double-blind, crossover comparative study on the gastroduodenal tolerablility of a highly specific cyclooxygenase-2 inhibitor, flosulide, and naproxen. Scand J Gastroenterol, 32, 126-130.
16. Caignard A, Martin M, Reisser D, Thomas B, Martin F (1984). Effects of cimetidine and indomethacin on the growth of dimethylhydrazine-induced or transplanted intestinal cancers in the rat. Br J Cancer, 50, 661-5.
17. Cassidy A, Bingham SA, Cummings JH (1994) Starch intake and colorectal cancer risk: an international comparison. Br J Cancer, 69, 937-942.
18. Castonguay A, Rioux N (1997). Inhibition of lung carcinogenesis by sulindac: comparison of two experimental protocols. Carcinogenesis, 18, 491-6.
19. Chan G, Boyle JO, Yang EK et al. (1999). Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. Cancer Res, 59, 991-4.
20. Coffey RJ. Hawkey CJ. Damstrup L et al. (1997). Epidermal growth factor receptor activation induces nuclear targeting of cyclooxygenase-2, basolateral release of prostaglandins, and mitogenesis in polarizing colon cancer cells. Proc?Natl Acad Sci USA, 94, 657-62.
21. Coleman RA, Smith WL, Narumiya S (1994). International Union of Pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes. Pharmacol Rev, 46, 205-229.
22. Cornwall H, Odukoya O, Shklar G (1983). Oral mucosal tumor inhibition by ibuprofen. Oral Maxillofac Surg, 41, 795-800.
23. Crofford LJ (1997). COX-1 and COX-2 tissue expression: implications and predictions. J Rheum, 24, 15-19.
24. Danzi M, Ferulano GP, Abate S, Califano G (1984). Enhancement of colonic cancer by indomethacin treatment in dimethylhydrazine pretreated rats. Carcinogenesis, 5, 287-9.
25. Deininger MH, Weller M, Streffer J, Mittelbronn M, Meyermann R (1999). Patterns of cyclooxygenase-1 and -2 expression in human gliomas in vivo. Acta Neuropathol, 98, 240-4.
26. Denda A, Endoh T, Tang Q, et al. (1998). Prevention by inhibitors of arachidonic acid cascade of liver carcinogenesis, cirrhosis and oxidative DNA damage caused by a choline-deficient, Lamino acid-defined diet in rats. Mutat Res, 402, 279-88.
27. Denda A, Tang Q, Endoh T, et al. (1994). Prevention by acetylsalicylic acid of liver cirrhosis and carcinogenesis as well as generations of 8-hydroxydeoxyguanosine and thiobarbituric acid-reactive substances caused by a choline-deficient, Lamino acid-defined diet in rats. Carcinogenesis, 15, 12379-83.
28. Dewitt DL, Meade EA (1993). Serum and glucocoricoid regulation of gene transcription and expression of prostaglandin synthase-1 and of prostaglandin synthase-2 isozymes. Arch Biochem Biophys, 306, 94-102.
29. Droller MJ, Gomolka D (1984). Indomethacin and poly I:C in the inhibition of carcinogen-induced bladder cancer in an experimental animal model. J Urol, 131, 1212-7.
30. Dubois RN, Abramson SB, Crofford L, et al. (1998). Cyclooxygenase in biology and disease. FASEB J, 12, 1063-73.
31. Dubois RN, Gupta R, Brockman J, et al. (1998). The nuclear eicosanoid receptor, PPARgamma, is aberrantly expressed in colonic cancers. Carcinogenesis, 19, 49-53.
32. Dubois RN, Radhika A, Reddy BS, Entingh AJ (1996). Increased cyclooxygenase-2 levels in carcinogen-induced ratcolonic tumors. Gastroenterology., 110, 1259-62.
33. Eberhart CE, Coffey RJ, Radhika A, et al. (1994). Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology, 107, 1183-8.
34. El Attar TM, Virji AS (1997. Effects of indomethacin, cisplatin and delta 12-prostaglandin J2 on growth of oral squamous carcinoma cells. Anticancer Res, 17, 4399-402.
35. El-Bayoumy K, Iatropoulos M, Amin S, Hoffmann D, Wynder EL (1999). Increased expression of cyclooxygenase-2 in rat lung tumors induced by the tobacco-specific nitrosamine 4-(methylnitrosamino)-4-(3-pyridyl)-1-butanone: the impact of a high-fat diet. Cancer Res, 59, 1400-3,.
36. Eling TE, Curtis JF (1992). Xenobiotic metabolism by prostaglandin H synthase. Pharmacol Ther, 53, 261-73.
37. Erickson BA, Longo WE, Panesar N, Mazuski JE, Kaminski DL (1999). The effect of selective cyclooxygenase inhibitors on intestinal epithelial cell mitogenesis. J Surg Res, 81, 101-7.
38. Ethridge RT, Hellmich MR, Dubois RN, Evers BM (1998). Inhibition of heat-shock protein 70 induction in intestinal cells overexpressing cyclooxygenase 2. Gastroenterology, 115, 1454-63.
39. Farrow DC, Vaughan TL, Hansten PD, et al. (1998) The use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer. Cancer Epidemiol Biomarkers Prevent, 7, 97-102.
40. Fischer SM, Lo H-H, Gordon GB, et al. (1999). Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, and indomethacin against ultraviolet light-induced skin carcinogenesis. Mol Carcinogen, 25, 231-40.
41. Fu S, Ramanujam KS, Wong A, et al (1999). Increased expression and cellular localization of inducible nitric oxide synthase and cyclooxygenase 2 in Helicobacter pylori gastritis. Gastroenterology, 116, 1319-29.
42. Fukutake M, Nakatsugi S, Isaoi T, et al. (1998) Suppressive effects of nimesulide, a selective inhibitor of cyclooxygenase-2 on azoxymethane-induced colon carcinogenesis in ice. Carcinogenesis, 19, 1939-42.
43. Funk CD, Funk LB, Kennedy ME, Pong AS, FitzGerald GA (1991) Human platelet/eryhthroleukemia cell prostaglandin G/H synthase: cDNA cloning expression, and gene chromosomal assignment. FASEB J, 5, 2304-12.
44. Funkhouser EM, Sharp G (1995). Aspirin and reduced risk of esophageal carcinoma. Cancer, 76, 1116-9.
45. Gann PH, Manson JE, Glynn CH, et al (1993). Low dose aspirin and incidence of colorectal tumors in a randomized trial. J Natl Cancer Inst, 85, 1220-4.
46. Giardiello FM. Hamilton SR. Hylind LM et al (1997). Ornithine decarboxylase and polyamines in familial adenomatous polyposis. Cancer Res 57, 199-201.
47. Giardiello FM, Hamilton SR, Krush AJ, et al. (1993). Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Eng J Med, 328, 1313-6.
48. Giardiello FM. Offerhaus JA. Tersmette AC, et al. (1996). Sulindac induced regression of colorectal adenomas in familial adenomatous polyposis: evaluation of predictive factors. Gut, 38, 578-81.
49. Giardiello FM, Spannhake EW, Dubois RN, et al (1998). Prostaglandin levels in human colorectal mucosa: effects of sulindac in patients with familial adenomatous polyposis. Dig Dis Sci, 43, 311-6.
50. Giovannucci E, Egan KM, Hunter DJ, et al. (1995). Aspirin and the risk of colorectal cancer in women. N Eng J Med, 333, 609-14.
51. Giovannucci E. Rimm EB. Stampfer MJ, et al. (1994). Aspirin use and the risk for colorectal cancer and adenoma in male health professionals [see comments]. Ann Int Med, 121, 241-6.
52. Goldman AP, Williams CS, Sheng H, et al. (1998). Meloxicam inhibits the growth of colorectal cancer cells. Carcinogenesis, 19, 2195-9.
53. Goodwin DC, Landino LM, Marnett LJ (1999). Effects of nitric oxide and nitric oxide-derived species on prostaglandin endoperoxide synthase and prostaglandin biosynthesis. FASEB J, 13, 11121-36.
54. Gridley G, McLaughlin JK, Ekbom A, et al. (1993). Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst, 85, 307-11.
55. Grubbs CJ, Juliana MM, Eto I, et al. (1993). Chemoprevention by indomethacin of n-butyl-n-(4-hydroxybutyl)-nitrosamineinduced urinary bladder tumors. Anticancer Res, 13, 33-36.
56. Gupta RA, Dubois RN (1998). Aspirin, NSAIDS, and colon cancer prevention: mechanisms? Gastroenterology, 114, 1095-8.
57. Hamasaki Y, Kitzler J, Hardman R, Nettesheim P, Eling TE (1993). Phorbol ester and epidermal growth factor enhance the expression of two inducible prostaglandin H synthase genes in rat tracheal epithelial cells. Arch Biochem Biophys, 304, 226-34.
58. Hanif R, Pittas A, Feng Y, et al. (1996). Effects of nonsteroidal antiinflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin-independent pathway. Biochem Pharmacol, 52, 237-45.
59. Habib A, Creminon C, Frobert Y, et al. (1993). Demonstration of an inducible cyclooxygenase in human endothelial cells using antibodies raised against the carboxyl-terminal region of cyclooxygenase-2. J Biol Chem, 268, 23448-54.
60. Hamid R, Singh J, Reddy BS, Cohen LA (1999). Inhibition by dietary menhaden oil of cyclooxygenase-1 and -2 in Nnitrosomethylurea-induced rat mammary tumors. Int J Oncol, 14, 523-8.
61. Hao X, Bishop AE, Wallace M, et al. (1999). Early expression of cyclo-oxygenase-2 during sporadic colorectal carcinogenesis. J Pathol, 187, 295-301.
62. Hara A, Yoshimi N, Niwa M, Ino N, Mori H (1997). Apoptosis induced by NS-398, a selective cyclooxygenase-2 inhibitor, in human colorectal cancer cell lines. Jpn J Cancer Res, 88, 600-4.
63. Harris RE, Namboodiri KK, Farrar WB (1996). Non-steroidal antiinflammatory drugs and breast cancer. Epidemiology, 7, 203-205.
64. Herschman HR (1996). Prostaglandin synthase 2. Biochim Biophys Acta, 1299, 125-140.
65. Hida T, Leyton J, Makheja AN, et al. (1998). Non-small cell lung cancer cycloxygenase activity and proliferation are inhibited by non-steroidal antiinflammatory drugs. Anticancer Res, 18, 775-82.
66. Hirata K, Itoh H, Ohsato K (1994). Regression of rectal polyps by indomethacin suppository in familial adenomatous polyposis. Report of two cases. [Comment in: Dis Colon Rectum 1995 Jun;38(6):668-9]. Dis Colon Rectum, 37, 943-6.
67. Hixson LJ, Alberts DS, Krutzsch M, et al. (1994). Antiproliferative effect of nonsteroidal antiinflammatory drugs against human colon cancer cells. Cancer Epidemiol Biomarkers Prevent, 3, 433-8.
68. Hoff T, Dewitt D, Kaever V, Resch K, Goppelt-Struebe M (1993). Differentiation-associated expression of prostaglandin G/H synthase in monocytic cells. FEBS Lett, 320, 38-42.
69. Holt PR, Mokuolu AO, Distler P, Liu T, Reddy BS (1996). Regional distribution of carcinogen-induced colonic neoplasia in the rat. Nutr Cancer, 25, 129-35
70. Huang M-T, Lou Y-R, Ma W, et al. (1994). Inhibitory effects of dietary curcumin on forestomach, duodenal and colon carcinogenesis in mice. Cancer Res, 54, 5841-7.
71. Huang M-T, Smart RC, Wong C-Q, Conney AH (1988). Inhibitory effect of curcumin, chlorogenic acid, caffeic acid and ferulic acid on tumor promotion in mouse skin by 12-Otetradecanoylphorbol-13-acetate. Cancer Res, 48, 5941-6.
72. Huang T-S, Lee S-C, Lin J-K (1991). Suppression of c-jun/AP-1 activation by an inhibitor of tumor promotion in mouse fibroblast cells. Proc Natl Acad Sci USA, 88, 5292-6.
73. IARC (1994). Schistosomes, liver flukes and Helicobacter pylori. Mongr. Evaluation of Carcinogenic Risks Human., 61, Lyon
74. IARC (1997). Handbooks of Cancer Prevention, Vol 1. Nonsteroidal anti-inflammatory drugs.
75. Inano H, Onoda M, Inafuku N, et al. (1999). Chemoprevention by curcumin during the promotion stage of tumorigenesis of mammary gland in rats irradiated with gamma-rays. Carcinogenesis, 20, 1011-8.
76. Inano H. Suzuki K. Onoda M. Wakabayashi K (1997). Anticarcinogenic activity of simvastatin during the promotion phase of radiation-induced mammary tumorigenesis of rats. Carcinogenesis, 18, 1723-7.
77. Inoue H, Yokoyama C, Hara S, Tone Y, Tanabe T (1995) Transcriptional regualtion of human prostaglandinendoperoxide synthase-2 gene by lipopolysaccharide and phorbol ester in vascular endothelial cells. Involvement of both nuclear factor for interleukin-6 expression site and cAMP response element. J Biol Chem, 270, 24965-71.
78. Ishikawa H, Akedo I, Suzuki T, Nakahara H, Otani T (1997). Adverse effects of sulindac used for prevention of colorectal cancer. J Natl Cancer Inst, 89, 1381.
79. Ishikawa T, Ichikawa Y, Tarnawski A, et al. (1998). Indomethacin interferes with EGF-induced activation of ornithine decarboxylase in gastric cancer cells. Digestion, 59, 47-52.
80. Isomäki HA, Hakulinen T, Joutsenlahti U (1978). Excess risk of lymphomas, leukemia, and myeloma in patients with rheumatoid arthritis. J Chron Dis, 31, 691-6.
81. Jalbert G, Castonguay A (1992). Effects of NSAIDs on NNKinduced pulmonary and gastric carcinogenesis in A/J mice. Cancer Lett, 66, 21-8.
82. Jones DA, Carlton DP, McIntyre TM, Zimmerman GA, Prescott SM (1993). Molecular cloning of human prostaglandin endoperoxide synthase type II and demonstration of expression in response to cytokines. J Biol Chem, 268, 9049-54.
83. Kargman SL, O'Neil GP, Vickers PJ, et al. (1995). Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer. Cancer Res, 55, 2556-9.
84. Karnes WE Jr, Shattuck-Brandt R, Burgart LJ, et al (1998). Reduced COX-2 protein in colorectal cancer with defective mismatch repair. Cancer Res, 58, 5473-7.
85. Kawamori T, Lubet R, Steele VE, et al. (1999). Chemopreventive effect of curcumin, a naturally occurring anti-inflammatory agent, during the promotion/progression stages of colon cancer. Cancer Res, 59, 597-601.
86. Kawamori T, Rao CV, Seibert K, Reddy BS (1998). Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res, 58, 409-12.
87. Kelley DJ, Mestre JR, Subbaramaiah K, et al. (1997). Benzo[a]pyrene up-regulates cyclooxygenase-2 gene expression in oral epithelial cells. Carcinogenesis, 18, 795-99.
88. Kestler M, Coroneos E, Thoams PJ, Dunn MJ (1994). Endothelin stimulates prostaglandin endoperoxide synthase-2 mRNA expression and protein synthesis through a tyrosine kinasesignaling pathway in rat mesangial cells. J Biol Chem, 269, 22574-80.
89. Kinoshita T, Takahashi Y, Sakashita T, et al. (1999). Growth stimulation and induction of epidermal growth factor receptor by overexpression of cyclooxygenases 1 and 2 in human colon carcinoma cells. Biochim Biophys Acta, 1438, 120-30.
90. Klän R, Knispel HH, Meier T (1993). Acetylsalicyclic acid inhibition of N-butyl(4-hydroxybutyl)nitrosamine-induced bladder carcinogenesis in rats. J Cancer Res Clin Oncol, 119, 482-5.
91. Koga H. Sakisaka S. Ohishi M, et al. (1999). Expression of cyclooxygenase-2 in human hepatocellular carcinoma: relevance to tumor dedifferentiation. Hepatology, 29, 688-96.
92. Kosaka T, Miyata A, Ihara H, et al. (1994). Characterization of the human gene (PTGS2) encoding prostaglandin-endoperoxidase synthase 2. Eur J Biochem, 221, 889-97.
93. Kroll B, Kunz S, Klein T, Schwarz LR (1999). Effect of lindane and phenobarbital on cyclooxygenase-2 expression and prostanoid synthesis by Kupffer cells. Carcinogenesis, 20, 1411-6.
94. Kudo T, Narisawa T, Abo S (1980). Antitumor activity of indomethacin on methylazoxymethanol-induced large bowel tumors in rats. Gann, 34, 260-4.
95. Kujubu DA, Herschman HR (1992). Dexamethasone inhibits mitogen induction of the TIS10 prostaglandin synthase/ cyclooxygenase gene. J Biol Chem, 267, 7991-4.
96. Kulkarni N, Zang E, Kelloff G, Reddy BS (1992). Effect of the chemopreventive agents piroxicam and D,L-alphadifluoromethylornithine on intermediate biomarkers of colon carcinogenesis. Carcinogenesis,13, 995-1000.
97. Kune GA, Kune S, Watson LF (1988). Colorectal cancer risk, chronic illnesses, operations, and medications: case control results from the Melbourne Colorectal Cancer Study. Cancer Res, 48, 4399-404.
98. Kurumbail RG, Stevens AM, Gierse JK, et al. (1996). Structural basis for selective inhibition of cyclooxygenase-2 by antiinflammatory agents. Nature, 384, 644-8.
99. Kusuhara H, Matsuyuki H, Matsuura M, et al. (1998). Induction of apoptotic DNA fragmentation by nonsteroidal antiinflammatory drugs in cultured rat gastric mucosal cells. Eur J Pharmacol, 360, 273-80.
100. Labayle D, Fisher D, Vielh P, et al. (1991). Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology, 101, 635-9.
101. Lee SH, Soyoola E, Chanmugam P, et al. (1992). Selective expression of mitogen-inducible cyclooxygenase in macrophages stimulated by lipopolysaccharide. J Biol Chem, 267, 25934-8.
102. Levine L (1977). Chemical carcinogens stimulate canine kidney (MDCK) cells to produce prostaglandins. Nature, 268, 447-8.
103. Li H, Schut AJ, Conran P, et al. (1999). Prevention by aspirin and its combination with a-difluoromethylornithine of azoxymethaneinduced timors, aberrant crypt foci and prostaglandin E2 levels in rat colon. Carcinogenesis, 20, 425-30.
104. Liang Y-C, Huang Y-T, Tsai S-H, et al. (1999). Suppression of inducible cyclooxygenase and inducible nitric oxide synthase by apigenin and related flavonoids in mouse macrophages. Carcinogenesis, 20, 1945-52.
105. Lipsky LP, Abramson SB, Crofford L, et al. (1998). The classification of cyclooxygenase inhibitors. J Rheumatol,. 25, 2298-303.
106. Lord RV, Danenberg KD, Danenberg PV (1999). Cyclooxygenase-2 in Barrett's esophagus, Barrett's adenocarcinomas, and esophageal SCC: ready for clinical trials. Am J Gastroenterol, 94, 2313-5.
107. Lupulescu A (1996) Prostaglandins, their inhibitors and cancer. Prostagland Leukotriene Essent Fatty Acids, 54, 83-94.
108. MacPhee M, Chepenik K, Liddell R, et al. (1995). The secretory phospholipase A2 gene is a candidate for the Mom 1 locus, a major modifier of Apamin-induced intestinal neoplasia. Cell, 81, 957-66.
109. Marks F, Furstenberger G, Muller-Decker K (1999). Metabolic targets of cancer chemoprevention: interruption of tumor development by inhibitors of arachidonic acid metabolism. Recent Res Cancer Res, 151, 45-67.
110. McCarthy CJ, Crofford LJ, Greenson J, Scheiman JM (1999). Cyclooxygenase-2 expression in gastric antral mucosa before and after eradication of Helicobacter pylori infection. Am J Gastroenterol, 94, 1218-23.
111. McEntee MF, Chiu C-H, Whelan J (1999). Relationship of ß-catenin and Bcl-2 expression to sulindac-induced regression of intestinal tumors in Min mice. Carcinogenesis, 20, 635-40.
112. McCormick DL, Madigan MJ, Moon RC (1985). Modulation of rat mammary carcinogenesis by indomethacin. Cancer Res, 45, 1803-8.
113. McCormick DL, Moon RC (1983). Inhibition of rat mammary carcinogenesis by by flurbiprofen, a nonsteroidal antiinflammatory agent. Br J Cancer, 48, 859-861.
114. Meng CL, Yang CY, Shen KL, Wong PY, Lee HK (1998). Inhibition of the synthesis of eicosanoid-like substances in a human oral cancer cell line by interferon-gamma and eicosapentaenoic acid. Arch Oral Biol, 43, 979-86
115. Mestre JR, Subbaramaiah K, Sacks PG, et al. (1997). Retinoids suppress epidermal growth factor-induced transcription of cyclooxygenase-2 in human oral squamous carcinoma cells. Cancer Res, 57, 2890-5.
116. Miyamoto T, Ogino N, Yamamoto S, Hayaishi O (1976). Purification of prostaglandin endoperoxide synthetase from bovine vesicular gland microsomes. J Biol Chem, 251, 2626-36.
117. Molina MA, Sitja-Arnau M, Lemoine MG, Frazier ML, Sinicrope FA (1999). Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: growth inhibition by nonsteroidal anti-inflammatory drugs. Cancer Res, 59, 4356-62.
118. Moon RC, Kelloff GJ, Detrisac CJ, et al., 1993). Chemoprevention of OH-BBN-induced bladder cancer in mice by piroxicam. Carcinogenesis, 14, 1487-9.
119. Moore MA, Tsuda H (1998) Chronically elevated proliferation as a risk factor for neoplasia. Eur J Cancer Prev, 7, 353-85.
120. Moorghen M, Ince P, Finney KJ, et al. (1988). A protective effect of sulindac against chemically induced primary colonic tumours in mice. J Pathol, 156, 341-7.
121. Morita I, Schindler M, Regier MK, et al. (1995). Different intracellular locations for prostaglandin endoperoxide H synthase-1 and -2. J Biol Chem, 270, 10902-8.
122. Murasaki G, Zenser TV, Davis BB, Cohen SM (1984) Inhibition by aspirin of N-[4-(5-nitro-furyl)-2-thiazolyl]formamideinduced bladder carcinogenesis and enhancement of forestomach carcinogenesis. Carcinogenesis, 5, 53-5.
123. Murata H. Kawano S. Tsuji S, et al. (1999). Cyclooxygenase-2 overexpression enhances lymphatic invasion and metastasis in human gastric carcinoma. Am J Gastroenterol, 94, 451-5.
124. Muscat JE, Stellman SD, Wynder EL (1994). Nonsteroidal antiinflammatory drugs and colorectal cancer. Cancer 74: 1847-54.
125. Mutoh M,Takahashi M, Fukuda K, et al. (2000). Suppression of cyclooxygenase-2 promoter-dependent transcriptional activity in colon cancer cells by chemopreventive agents with a resorcin-type structure. Carcinogenesis, (in press)
126. Nakatsugi S. Fukutake M. Takahashi M, et al. (1997). Suppression of intestinal polyp development by nimesulide, a selective cyclooxygenase-2 inhibitor, in Min mice. Jpn J Cancer Res, 88, 1117-20.
127. Narisawa T. Hermanek P. Habs M. Schmahl D (1984). Reduction of acetoxymethyl-methylnitrosamine-induced large bowel cancer in rats by indomethacin. Tohoku J Exp Med, 144, 237-43.
128. Narisawa T, Satoh M, Sano M, Takahashi T (1983). Inhibition of initiation and promotion by N-methylnitrosourea-induced colon carcinogenesis in rats by non-steroid anti-inflammatory agent indomethacin. Carcinogenesis. 4, 1225-7.
129. Narisawa T, Takahashi M, Niwa M, Fukaura Y, Wakizaka A (1987). Involvement of prostaglandin E2 in bile acid-caused promotion of colon carcinogenesis and anti-promotion by the cyclooxygenase inhibitor indomethacin. Jpn J Cancer Res, 78, 791-8.
130. Nicolopoulos N, Mantidis A, Stathopoulos E, et al. (1985). Prophylactic administration of indomethacin for irradiation esophagitis. Radiother Oncol, 3, 23-5.
131. Nigro ND, Bull AW, Boyd ME (1986) Inhibition of intestinal carcinogenesis in rats: effect of dimethylornithine with piroxicam or fish oil. J Natl Cancer Inst, 77, 1309-1313.
132. Nugent KP, Spiegelman AD, Phillips RK (1996). Tissue prostaglandin levels in familial adenomatous polyposispatients treated with sulindac. Dis Colon Rect, 39, 659-62.
133. Ochiai M, Oguri T, Isobe T, Ishioka S, Yamakido M (1999). Cyclooxygenase-2 (COX-2) mRNA expression levels in normal lung tissues and non-small cell lung cancers. Jpn J Cancer Res, 90, 1338-43.
134. Ondrey FG, Juhn SK, Adams GL (1996). Inhibition of head and neck tumor cell growth with arachidonic acid metabolism inhibition. Laryngoscope, 106, 129-34.
135. Okajima E, Denda A, Ozono S, et al. (1998).Chemopreventive effects of nimesulide, a selective cyclooxygenase-2 inhibitor, on the development of rat urinary bladder carcinomas initiated by Nbutyl-N-(4-hydroxybutyl)-nitrosamine. Cancer Res 58, 3028-31.
136. O'mahony CA, Beauchamp RD, Albo D, et al. (1999). Cyclooxygenase-2 alters transforming growth factor-beta 1 response during intestinal tumorigenesis. Surgery, 126, 364-70.
137. Oshima M, Dinchuk JE, Kargman SL, et al. (1996). Suppression of intestinal polyposis in Apc716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell, 87, 803-9.
138. Oshima M, Oshima H, Kitagawa K, et al. (1995a). Loss of Apc heterozygosity in nascent intestinal polyps in mice carrying a truncated Apc gene. Proc Natl Acad Sci USA, 92, 4482-4486.
139. Oshima M, Takahashi M, Oshima H, et al. (1995b). Effects of docosahexaenoic acid (DHA) on intestinal polyp development in Apc?716 knockout mice. Carcinogenesis, 11, 2605-7.
140. Ota S. Tanaka Y. Bamba H. Kato A. Matsuzaki F (1999). Nonsteroidal anti-inflammatory drugs may prevent colon cancer through suppression of hepatocyte growth factor expression. Eur J Pharmacol, 367, 131-8.
141. Otto JC, Dewitt DL, Smith WL (1993). N-glycosylation of prostaglanding endoperoxide synthases-1 and -2 and their orientations in the endoplasimic reticulum. J Biol Chem, 268, 18234-42.
142. Ozaki M. Shibata MA. Takahashi S, et al. (1997). Lack of involvement of p53 gene mutations in N-methyl-Nnitrosourea-induced bladder tumor progression in N-butyl-N-(4-hydroxybutyl)nitrosamine-treated rats and no suppression by indomethacin. Cancer Letters, 115, 249-55.
143. Paganini-Hill A, Chao A, Ross RK, Henderson BE (1989) Aspirin use and chronic diseases: a cohort study of the elderly. Br Med J, 299, 1247-50.
144. Parrett ML, Harris RE, Joarder FS, et al. (1997). Cycooxygenase-2 gene expression in human breast cancer. Int J Oncol, 10, 503-7.
145. Pasricha PJ. Bedi A. O'Connor K., et al. (1995). The effects of sulindac on colorectal proliferation and apoptosis in familial adenomatous polyposis Gastroenterology, 109, 994-8.
146. Peleg II, Lubin MF, Cotsonis GA, Clark WS, Wilcox CM (1996). Long-term use of non-steroidal antiinflammatory drugs and other chemopreventors and risk of subsequent colorectal neoplasia. Dig Dis Sci, 41, 1319-1326.
147. Pentland AP, Schoggins JW, Scott GA, Khan KNM, Han R (1999). Reduction of UV-induced skin tumors in hairless mice by selective COX-2 inhibition. Carcinogenesis, 20, 1939-44.
148. Pepin P, Bouchard L, Nicole P, Castongauay A (1992). Effects of sulindac and oltipraz on the tumorigenicity of 4(methylnitrosamino)-1-(3-pyridyl)-1-butanone in A/J mouse lung. Carcinogenesis, 13, 341-348.
149. Pereira MA, Barnes LH, Steele VE, et al. (1996). Piroxicam-induced regression of azoxymethane-induced aberrant crypt foci and prevention of colon cancer in rats. Carcinogenesis, 17, 373-6.
150. Perkins TM, Shklar G (1982). Delay in hamster buccal pouch carcinogenesis by aspirin and indomethacin. Oral Surg, 53, 170-8.
151. Pollard M, Luckert PH (1984). Effects of piroxicam on primary intestinal tumors induced in rats by N-methylnitrosourea. Cancer Letters, 25, 117-21.
152. Preston-Martin S, Pike MC, et al. (1990). Increased cell division as a cause of human cancer. Cancer Res, 50, 7415-21.
153. Rao RA, Hussain SP (1988). Modulation of methylcholanthreneinduced carcinogenesis in the uterine cervix of mouse by indomethacin. Cancer Lett, 43, 15-9.
154. Rao CV, Kawamori T, Hamid R, Reddy BS (1999). Chemoprevention of colonic aberrant crypt foci by an inducible nitric oxide synthase-selective inhibitor. Carcinogenesis, 20, 641-4
155. Rao CV, Reddy BS (1993). Modulating effect of amount and types of dietary fat on ornithine decarboxylase, tyrosine protein kinase and prostaglandins production during colon carcinogenesis in male F344 rats. Carcinogenesis,14, 1327-33,.
156. Rao CV, Rivenson A, Simi B, et al. (1995a). Chemoprevention of colon carcinogenesis by sulindac, a nonsteroidal antiinflammatory agent. Cancer Res, 55, 1464-72.
157. Rao CV, Rivenson A, Simi B, Reddy BS (1995b). Chemoprevention of colon carcinogenesis by dietary curcumin, a naturally occurring plant phenolic compound. Cancer Res 55, 259-66.
158. Rao CV, Simi B, Reddy BS (1993). Inhibition by dietary curcumin of azoxymethane-induced ornithine decarboxylase, tyrosine protein kinase, arachidonic acid metabolism and aberrant crypt foci formation in the rat colon. Carcinogenesis, 14, 2219-25.
159. Rao CV, Simi B, Wynn TT, Garr K, Reddy BS (1996). Modulating effect of amount and types of dietary fat on colonic mucosal phospholipase A2, phosphatidylinositol-specific phospholipase C activities, and cyclooxygenase metabolite formation during different stages of colon tumor promotion in male F344 rats. Cancer Res, 56, 532-7.
160. Rao CV. Tokumo K. Rigotty J, et al. (1991). Chemoprevention of colon carcinogenesis by dietary administration of piroxicam, alpha-difluoromethylornithine, 16 alpha-fluoro-5-androsten-17-one, and ellagic acid individually and in combination. Cancer Res, 51, 4528-34.
161. Rao CV, Zang E, Reddy BS (1993). Effect of high fat corn oil, olive oil and fish oil on phospholipid fatty acid composition in male F344 rats. Lipids, 28, 441-7
162. Rao KVN, Detrisac CJ, Steele VE, et al. (1996) Differential activity of aspirin, ketoprofen and sulindac as cancer chemopreventive agents in the mouse urinary bladder. Carcinogenesis, 17, 1435-8.
163. Ratnasinghe D, Tangrea JA, Roth MJ, et al. (1999). Expression of cyclooxygenase-2 in human adenocarcinomas of the gastric cardia and corpus. Oncol Reports, 6, 965-8.
164. Ratnasinghe D, Tangrea J, Roth MJ, et al. (1999). Expression of cyclooxygenase-2 in human squamous cell carcinoma of the esophagus; an immunohistochemical survey. Anticancer Res, 19, 171-4.
165. Reddy ST, Herschman HR (1996). Transcellular prostaglandin production following mast cell activation is mediated by proximal secretory phospholipase A2 and distal prostaglandin synthase 1. J Biol Chem, 271, 186-191.
166. Reddy BS. Kawamori T. Lubet R et al. (1999a). Chemopreventive effect of S-methylmethane thiosulfonate and sulindac administered together during the promotion/progression stages of colon carcinogenesis. Carcinogenesis, 20, 1645-8.
167. Reddy BS, Kawamori T, Lubet RA, et al. (1999). Chemopreventive efficacy of sulindac sulfone against colon cancer depends on time of administration during carcinogenic process. Cancer Res, 59, 3387-91.
168. Reddy BS. Maruyama H. Kelloff G (1987). Dose-related inhibition of colon carcinogenesis by dietary piroxicam, a nonsteroidal antiinflammatory drug, during different stages of rat colon tumor development. Cancer Res, 47, 5340-6.
169. Reddy BS, Nayini J, Tokumo K et al. (1990). Chemoprevention of colon carcinogenesis by concurrent administration of piroxicam, a nonsteroidal antiinflammatory drug with D,Lalpha-difluoromethylornithine, an ornithine decarboxylase inhibitor, in diet. Cancer Res, 50, 2562-8.
170. Reddy BS. Rao CV. Rivenson A. Kelloff G (1993). Inhibitory effect of aspirin on azoxymethane-induced colon carcinogenesis in F344 rats. Carcinogenesis, 14, 1493-7.
171. Reddy BS, Rao CV, Seibert K (1996). Evaluation of cyclooxygenase-2 inhibitor for potential chemopreventive properties in colon carcinogenesis. Cancer Res, 56, 4566-9.
172. Reddy BS, Tokumo K, Kulkarni N, Aligia C, Kelloff G (1992). Inhibition of colon carcinogenesis by prostaglandin synthesis inhibitors and related compounds. Carcinogenesis 13, 1019-23.
173. Reeves MJ, Newcomb PA, Trentham-Dietz A, Storer BE, Remington PL (1996). Nonsteroidal anti-inflammatory drug use and protection against colorectal cancer in women. Cancer Epidemiol Biomarkers Prevent, 5, 955-60.
174. Rigas B, Goldman IS, Levine L (1993). Altered eicosanoid levels in human colon cancer. J Lab Clin Med, 122, 518-23.
175. Rioux N, Castonguay A (1998). Prevention of NNK-induced lung tumorigenesis in A/J mice by acetylsalicylic acid and NS-398. Cancer Res, 58, 5354-60.
176. Ristimaki A, Honkanen N, Jankala H, Sipponen P, Harkonen M. (1997). Expression of cyclooxygenase-2 in gastric carcinoma. Cancer Res, 57, 1276-80.
177. Ritland SR, Gendler SJ (1999). Chemoprevention of intestinal adenomas in the AppcMin mouse by piroxicam: kinetics, strain effects and resistance to chemosuppression. Carcinogenesis, 20, 51-8.
178. Rose DP, Connolly JM (1990). Effects of fatty acids and inhibitors of eicosanoid synthesis on the growth of a human breast cancer cell line in culture. Cancer Res, 50, 7139-44
179. Rosenberg L, Palmer JR, Zauber AG, et al. (1991). A hypothesis: nonsteroidal anti-inflammatory drugs reduce the incidence of large-bowel cancer. J Natl Cancer Inst, 83, 355-8.
180. Rubio CA (1984). Antitumoral activity of indomethacin on experimental esophageal tumors. J Natl Cancer Inst, 72, 705-7.
181. Rubio CA (1986). Further studies on the therapeutic effect of indomethacin on esophageal tumors. Cancer, 58, 1029-31.
182. Sakuma K, Fujimori T, Hirabayashi K, Terano A (1999). Cyclooxygenase (COX)-2 immunoreactivity and relationship to p53 and Ki-67 expression in colorectal cancer. J Gastroenterol. 34, 189-94.
183. Samaha HS, Kelloff GJ, Steele V, Rao CV, Reddy BS (1997). of apoptosis by sulindac, curcumin, phenylethyl-3-methylcaffeate, and 6 phenylhexyl isothiocyanate: apoptotic index as a biomarker in colon cancerchemoprevention and promotion. Cancer Res, 57, 1301-5.
184. Sano H, Kawahito Y, Wilder RL, et al. (1995). Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res, 55, 3785-9.
185. Sawaoka H, Kawano S, Tsuji S, et al. (1998). Cyclooxygenase-2 inhibitors suppress the growth of gastric cancer xenografts via induction of apoptosis in nude mice. Am J Physiol, 274, G1061-7.
186. Sawaoka H, Kawano S, Tsuji S, et al. (1998). Effects of NSAIDs on proliferation of gastric cancer cells in vitro: possible implication of cyclooxygenase-2 in cancer development. J Clin Gastroenterol, 27, S47-52.
187. Schreinemachers DM, Everson RB (1994). Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology, 5, 138-146.
188. Shafer AI (1995). Effects of nonsteroidal antiinflammatory drugs on platelet function and systemic hemostasis. J Clin Pharmacol, 35, 209-19.
189. Shao J, Sheng H, Aramandla R, et al. (1999). Coordinate regulation of cyclooxygenase-2 and TGF-beta1 in replication errorpositive colon cancer and azoxymethane-induced rat colonic tumors. Carcinogenesis, 20, 185-91.
190. Shattuck-Brandt RL, Lamps LW, Heppner Goss KJ, Dubois RN, Matrisian LM. (1999). Differential expression of matrilysin and cyclooxygenase-2 in intestinal and colorectal neoplasms. Mol Carcinogenesis, 24, 177-87.
191. Sheng H. Shao J. Morrow JD. Beauchamp RD. Dubois RN (1998a). Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res, 58, 362-6.
192. Sheng H. Shao J. O'mahony CA, et al. (1999). Transformation of intestinal epithelial cells by chronic TGF-beta1 treatment results in downregulation of the type II TGF-beta receptor and induction of cyclooxygenase-2. Oncogene, 18, 855-67.
193. Sheng GG, Shao J, Sheng H, et al. (1997). A selective cyclooxygenase 2 inhibitor suppresses the growth of H-rastransformed rat intestinal epithelial cells. Gastroenterology, 113, 1883-91.
194. Sheng H, Shao J, Williams CS, et al. (1998b). Nuclear translocation of beta-catenin in hereditary and carcinogen-induced intestinal adenomas. Carcinogenesis, 19, 543-9.
195. Sheng H, Williams CS, Shao J, et al. (1998c). Induction of cyclooxygenase-2 by activated Ha-ras oncogene in Rat-1 fibroblasts and the role of mitogen-activated protein kinase pathway. J Biol Chem, 273, 22120-7.
196. Shibata MA, Hasegawa R, Imaida K, et al. (1995). Chemoprevention by dehydroepiandrosterone and indomethacin in a rat multiorgan carcinogenesis model. Cancer Res, 55, 4870-4.
197. Shibata MA, Hasegawa R, Shirai T, Takesada Y, Fukushima S (1993). Chemoprevention by indomethacin of tumor promotion in a rat urinary bladder carcinogenesis model. Int J Cancer, 55, 1011-7.
198. Shiff SJ, Koutsos MI, Qiao L, Rigas B (1996). Nonsteroidal antiinflammatory drugs inhibit the proliferation of colon adenocarcinoma cells: effects on cell cycle and apoptosis. Exp Cell Res, 222, 179-88
199. Shimamura T, Takahashi S (1994). Reduced proliferation of cultured bladder cancer cells by indomethacin. New Jersey Med, 91, 532-4.
200. Shiota G, Okubo M, Noumi T, et al. (1999). Cyclooxygenase-2expression in hepatocellular carcinoma. Hepato-Gastroenterol, 46, 407-12.
201. Simmons DL, Levy DB, Yannoni Y, Erikson RL (1989). Identification of a phorbol ester-repressible v-src-inducible gene. Proc Natl Acad Sci USA, 86, 1178-1182.
202. Singh J, Hamid R, Reddy BS (1997). Dietary fat and colon cancer: modulating effect of types and amount of dietary fat on rasp21 function during promotion and progression stages of colon cancer. Cancer Res, 57, 253-8.
203. Singh J, Hamid R, Reddy BS (1997). Dietary fat and colon cancer: modulation of cyclooxygenase-2 by types and amount of dietary fat during the postinitiation stage of colon carcinogenesis. Cancer Res, 57, 3465-70.
204. Singh J, Hamid R, Reddy BS (1998). Dietary fish oil inhibits the expression of farnesyl protein transferase and colon tumor development in rodents. Carcinogenesis, 19, 985-9.
205. Singh J. Reddy BS (1995). Molecular markers in chemoprevention of colon cancer. Inhibition of expression of ras-p21 and p53 by sulindac during azoxymethane-induced colon carcinogenesis. Ann New York Acad Sci, 768, 205-9
206. Skinner SA, Penney AG, O'Brien PE (1991) Sulindac inhibits the rate of growth and appearance of colon tumors in the rat. Arch Surg, 126, 1094-6.
207. Steele VE. Holmes CA. Hawk ET, et al. (1999). Lipoxygenase inhibitors as potential cancer chemopreventives. Cancer Epidemiol Biomarkers Prevent, 8, 467-83.
208. Subbaramaiah K, Altorki N, Chung WJ, et al. (1999). Inhibition of cyclooxygenase-2 gene expression by p53. J Biol Chem, 274, 10911-5.
209. Subbaramaiah K, Chung WJ, Dannenberg AJ (1998). Ceramide regulates the transcription of cyclooxygenase-2. Evidence for involvement of extracellular signal-regulated kinase/c-Jun Nterminal kinase and p38 mitogen-activated protein kinase pathways. J Biol Chem, 273, 32943-9.
210. Subbaramaiah K, Zakim D, Weksler BB, Dannenberg AJ (1997). Inhibition of cyclooxygenase: a novel approach to cancer prevention. Proc Soc Exp Biol Med, 216, 201-210.
211. Sugie S. Okamoto K. Tanaka T, et al. (1995). Effect of fish oil on the development of AOM-induced glutathione S-transferase placental form positive hepatocellular foci in male F344 rats.Nutr Cancer, 24, 187-95.
212. Sugimura T (1996). An overview of cancer prevention. Eur J Cancer Prev, 5, 1-8.
213. Sugimura T (1997). Overview of carcinogenic heterocyclic amines. Mutat Res, 376, 211-9.
214. Suh O, Mettlin C, Petrelli NJ (1993). Aspirin use, cancer, and polyps of the bowel. Cancer, 72, 1171-7.
215. Suzui N, Sugie S, Rahman KM, et al. (1997). Inhibitory effects of diallyl disulfide or aspirin on 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine-induced mammary carcinogenesis in rats. Jpn J Cancer Res, 88, 705-11.
216. Takahashi M, Fukuda K, Ohata T, Sugimura T, Wakabayashi K (1997). Increased expression of inducible and endothelial constitutive nitric oxide synthases in rat colon tumors induced by azoxymethane. Cancer Res, 57, 1233-7.
217. Takahashi M, Fukutake M, Isoi T, et al. (1997a). Suppression of azoxymethane-induced rat colon carcinoma development by a fish oil component, docosahexaenoic acid (DHA). Carcinogenesis, 18, 1337-42.
218. Takahashi M, Fukutake M, Yokota S, et al. (1996). Suppression of azoxymethane-induced aberrant crypt foci in rat colon by nimesulide, a selective inhibitor of cyclooxygenase 2. J Cancer Res Clin Oncol, 122, 219-22.
219. Takahashi M, Furukawa F, Toyoda K, et al. (1990). Effects of various prostaglandin synthesis inhibitors on pancreatic carcinogenesis in hamsters after initiation with N-nitrosobis(2-oxopropyl)amine. Carcinogenesis, 11, 393-5.
220. Takahashi M. Totsuka Y. Masuda M et al. (1997b). Reduction in formation of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP)-induced aberrant crypt foci in the rat colon by docosahexaenoic acid (DHA). Carcinogenesis, 18, 1937-41.
221. Tanaka T, Kojima T, Okumura A, Sugie S, Mori H (1993). Inhibitory effects of the non-steroidal anti-inflammatory drugs, indomethacin and piroxicam on 2-acetylaminofluoreneinduced hepatocarcinogenesis in male ACI/N rats. Cancer Lett, 68, 111-118.
222. Tanaka T, Kojima T, Yoshimi N, Sugie S, Mori H (1991). Inhibitory effect of the non-steroidal anti-inflammatory drug, indomethacin on the naturally occurring carcinogen, 1-hydroxyanthraquinone in male ACI/N rats. Carcinogenesis, 12, 1949-52.
223. Tanaka T, Makita H, Ohnishi M, et al. (1994). Chemoprevention of 4-nitroquinoline 1-oxide-induced oral carcinogenesis by dietary curcumin and hesperidin: comparison with the protective effect of ß-carotene. Cancer Res, 54, 4653-59.
224. Tanaka T, Nishikawa A, Mori Y, Morishita Y, Mori H (1989). Inhibitory effects of non-steroidal anti-inflammatory drugs, piroxicam and indomethacin on 4-nitroquinoline 1-oxideinduced tongue carcinogenesis in male ACI/N rats [published erratum appears in Cancer Lett 1990 Apr 20;50(2):165]. Cancer Lett, 48, 177-82
225. Thompson HJ, Jiang C, Lu J, et al (1997). Sulfone metabolite of sulindac inhibits mammary carcinogenesis. Cancer Res 57: 267-71.
226. Thun MJ, Namboodiri MM, Calle EE, Flanders DW, Heath CW Jr. (1993). Aspirin use and risk of fatal cancer. Cancer Res, 53, 1322-7.
227. Trevethick MA, Oakley I, Clayton NM, Strong P (1995). Nonsteroidal anti-inflammatory drug-induced gastric damage in experimental animals: underlying pathological mechanisms. Gen Pharmacol, 26, 1455-9.
228. Tsujii M, Dubois RN (1995). Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell, 83, 493-501.
229. Tsujii M. Kawano S. Dubois RN (1997). Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci USA, 94, 3336-40.
230. Tsujii M, Kawano S, Tsuji S, et al. (1998). Cyclooxygenase regulates angiogenesis induced by colon cancer cells [published erratum appears in Cell 1998 Jul 24;94(2):following 271]. Cell, 93, 705-16.
231. Tucker ON, Dannenberg AJ, Yang EK, et al. (1999). Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. Cancer Res, 59, 987-90.
232. Ueda N, Yamashita R, Yamamoto S, Ishimura K (1997). Induction of cyclooxygenase-1 in a human megakaryoblastic cell line (CMK) differentiated by phorbol ester. Biochim Biophys Acta, 1344, 103-110.
233. Ushikubi F, Hirata M, Narumiya S (1995). Molecular biology of prostanoid receptors; an overview. J Lipid Mediat Cell Signal, 12, 343-59.
234. Ushikubi F, Segi E, Sugimoto Y, et al. (1998). Impaired febrile response in mice lacking the prostaglandin E receptor subtype EP3. Nature, 395, 281-4.
235. Vane JR (1971). Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature, 231, 232-5.
236. Wakabayashi K, Totsuka Y, Fukutome K et al. (1997). Human exposure to mutagenic/carcinogenic heterocyclic amines and comutagenic beta-carbolines. Mutat Res, 376, 253-9.
237. Wallace JL (1999). Selective COX-2 inhibitors: is the water becoming muddy? TiPS, 20, 4-6.
238. Wargovich MJ, Chen CD, Harris C, Yang E, Velasco M (1995) Inhibition of aberrant crypt growth by non-steroidal antiinflammatory agents and differentiation agents in the rat colon. Int J Cancer, 60, 515-9.
239. Watanabe K, Kawamori T, Nakatsugi S, et al. (1999). Role of the prostaglandin E receptor subtype EP1 in colon carcinogenesis. Cancer Res, 59, 5093-6.
240. Watanabe K, Kawamori T, Nakatsugi S, et al. (2000). Inhibitory effect of a prostaglandin E receptor subtype EP1 se;ective antagonist. ONO-8713, on development of azoxymethaneinduced aberrant crypt foci in mice. Journal?
241. Weitzman SA, Gordon LI. (1990). Inflammation and cancer: role of phagocyte-generated oxidants in carcinogenesis. Blood, 76, 655-63.
242. Williams CS, Dubois RN (1996). Prostaglandin endoperoxide synthase: why two isoforms? Am J Physiol, 270, G393-400.
243. Williams CW, Luongo C, Radhika A, et al. (1006). Elevated cyclooxygenase-2 levels in Min mouse adenomas.Gastroenterology, 111, 1134-40.
244. Williamson SL, Kartheuser A, Coaker J, et al. (1999). Intestinal tumorigenesis in the Apc1638N mouse treated with aspirin and resistant starch for up to 5 months. Carcinogenesis, 20, 805-10.
245. Wong BC, Zhu GH, Lam SK (1999). Aspirin induced apoptosis in gastric cancer cells. Biomed Pharmacother, 53, 315-8.
246. Xie W, Herschman HR (1995). v-src induces prostaglandin synthase-2 gene expression by activation of the c-Jun Nterminal kinase and the c-Jun transcription factor. J Biol Chem, 270, 27622-8.
247. Yang VW. Shields JM. Hamilton SR et al. (1998). Size-dependent increase in prostanoid levels in adenomas of patients with familial adenomatous polyposis. Cancer Res, 58, 1750-3.
248. Ylikorkala O, Kauppila A, Viinikka L (1983). Prostacyclin and thromboxane in ovarian cancer: effect of cytostatics and prostaglandin synthesis inhibitors. Gynecol Oncol, 16, 340-
249. Yoshimi N, Shimizu M, Matsunaga K, egt al. (1999). Chemopreventive effect of N-(2-cyclohexyloxy-4-nitrophenyl)methane sulfonamide (NS-398), a selective cyclooxygenase-2 inhibitor, in rat colon carcinogenesis induced by azoxymethane. Jpn J Cancer Res, 90, 406-12.
250. Zambraski EJ (1995). The effects of nonsteroidal anti-inflammatory drugs on renal function: experimental studies in animals. Semin Nephrol, 15, 205-13.
251. Zaridze D, Borisova E, Maximovitch D, Chkikvadze V (1999) Aspirin protects against gastric cancer: results of a case-control study from Moscow, Russia. Int J Cancer 82, 473-476
252. Zhang F, Altorki NK, Mestre JR, Subbaramaiah K, Dannenberg AJ (1999). Curcumin inhibits cyclooxygenase-2 transcription in bile acid- and phorbol ester-treated human gastrointestinal epithelial cells. Carcinogenesis, 20, 445-51.
253. Zhang T. Nanney LB. Luongo C, et al. (1997). Concurrent overexpression of cyclin D1 and cyclin-dependent kinase 4 (Cdk4) in intestinal adenomas from multiple intestinal neoplasia (Min) mice and human familial adenomatous polyposis patients. Cancer Res, 57, 169-75.
254. Zhang T, Nanney LB, Peeler MO, et al. (1997). Decreased transforming growth factor beta type II receptor expression in intestinal adenomas from Min/+ mice is associated with increased cyclin D1 and cyclin-dependent kinase 4 expression. Cancer Res, 57, 1638-43.
255. Zhu GH, Wong BC, Ching CK, Lai KC, Lam SK (1999). Differential apoptosis by indomethacin in gastric epithelial cells through the constitutive expression of wild-type p53 and/or upregulation of c-myc. Biochem Pharmacol, 58, 193-200.
256. Zhu GH, Wong BC, Eggo MC, et al. (1999). Non-steroidal antiinflammatory drug-induced apoptosis in gastric cancer cells is blocked by protein kinase C activation through inhibition of c-myc. Br J Cancer, 79, 393-400.
257. Zimmermann KC. Sarbia M. Weber AA, et al. (1999). Cyclooxygenase-2 expression in human esophageal carcinoma. Cancer Res, 59, 198-204.